Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — H1 FY2024 Earnings Presentation
32 slides from Lumos Diagnostics's earnings presentation, Feb 28, 2024
Slide 1: 1H FY24 Financial Results Presentation
Lumos Diagnostics Holdings Limited 1H FY24 Financial Results Presentation 28 February 2024 lumosdiagnostics.com 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Contents
Contents Company Overview 1H FY24 Financial Results Product Update Services Update Looking Ahead Questions 3
Slide 4: Company overview
Company overview Experienced leadership • Led by Doug Ward (CEO) - industry veteran with over 30 years' in diagnostics • Experienced business/technical/commercial leaders also include Lumos is a developer and Barrie Lambert (CFO); Sacha Dopheide (CTO) & Paul Kase (SVP Commercial Ops) manufacturer of
Slide 5: 1H FY24 Financial Results
1H FY24 Financial Results
Slide 6: 1H FY24 and Post Reporting – Highlights
1H FY24 and Post Reporting – Highlights* “ Revenue $2.8 million ($5.1 million 1H FY23) – resources focused on FebriDx/ViraDx launches and closing Hologic deal Having dedicated our limited resources to closing the Gross profit margin for 1H FY24 of 52%, an improvement of 6ppts over 1H FY23 Hologic de
Slide 7: Revenue & Gross Profit
Revenue & Gross Profit (US$ in thousands) REVENUE REVENUE MIX GROSS PROFIT $6,428 100% $6,500 $5,448 $4,000 $3,376 70% $5,087 62% $5,500 80% $3,500 $2,571 60% $2,353 $3,000 52% 50% $4,500 60% $2,500 46% $3,500 $2,766 40% $2,000 40% 40% $1,435 30% $2,500 $1,500 20% $1,000 20% $1,500 $500 10% $500 0%
Slide 8: OPEX & EBITDA
OPEX & EBITDA (US$ in thousands) OPERATING EXPENSES1 EBITDA2 NPAT3 2H FY22 1H FY23 2H FY23 1H FY24 $0 1H FY24 1H FY23 $12,000 $10,592 $'000 $'000 $10,000 -$2,000 Underlying EBITDA Loss (4,213) (3,901) $8,000 $6,254 -$2,040 $5,416 $5,648 -$4,000 $6,000 Depreciation & Amortisation (1,248) (1,949) -$3,
Slide 9: Cash Flow
Cash Flow (US$ in thousands) OPERATING INVESTING FINANCING & CASH BALANCE 1H FY24 1H FY23 1H FY24 1H FY23 1H FY24 1H FY23 $'000 $'000 $'000 $'000 $'000 $'000 Cash flows from investing activities Cash flows from financing activities Cash flows from operating activities Proceeds from issue of shares,
Slide 10: Balance Sheet
Balance Sheet (US$ in thousands) ASSETS LIABILITIES EQUITY 31 Dec 2023 30 Jun 2023 31 Dec 2023 30 Jun 2023 31 Dec 2023 30 Jun 2023 $'000 $'000 $'000 $'000 $'000 $'000 Assets Liabilities Current assets Current liabilities Equity Cash and cash equivalents 1,379 3,015 Trade and other payables 2,051 2,8
Slide 11: Product Update
Product Update
Slide 12: FebriDx Launch - US product sales
FebriDx Launch- US product sales Commenced sales & marketing activities to initial key customers • Commenced selling FebriDx in the US in January 2024 • Agreements with 14 customers/distributors in place • Henry Schein distribution agreement executed February 2024 • 50 lab specialists; Providing exp
Slide 13: FebriDx: Addressing a major need: antibiotic overprescription
FebriDx: Addressing a major need: antibiotic overprescription ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED HOW WE’RE DRIVING MARKET ADOPTION Common cold Marketing and education Sinusitis • Microbial testing prior to prescribing antibiotics not currently routine Other infections
Slide 14: US - CDC flu map
US - CDC flu map Current flu season infections continue to increase in the US: • Flu season expected to continue through to April 2024 • Sales windows for FebriDx and ViraDx extended 14
Slide 15: ViraDx – Lumos' POC test for key respiratory infections
ViraDx™ – Lumos’ POC test for key respiratory infections ViraDx highly relevant POC test for post-pandemic environment: • SARS-CoV-2 pandemic increased consumer and healthcare POC testing • ViraDx is a 3-in-1 test for COVID-19/’flu A/’flu B • One of two tests available in market that provides visual
Slide 16: Services Update
Bikcwos ices Update”
Slide 17: Hologic - new major development and IP agreements
Hologic - new major development and IP agreements* Focus on improving one of Hologic's leading on-market women's health products and adapting it for use on Lumos’ proprietary reader platform. Collaboration Builds on work jointly conducted over last 12+ months These new contracts Fetal fibronectin st
Slide 18: Fetal Fibronectin (fFN) background
Fetal Fibronectin (fFN) background A biomarker indicating a heightened risk of pre-term delivery when present in cervicovaginal secretions fFN is the largest segment in the • Background pre-term diagnostic test kit market • fFN is protein found at the maternal-fetal interface. As delivery approaches
Slide 19: Hologic - fFN product development overview
Hologic - fFN product development overview Current test: Rapid fFN TLiQ Next generation test concept (mock-up) Benefits of the new technology • Latest state-of-the-art technology, with reader platform • Connectivity for improved digital patient record management • Developed and manufactured to lates
Slide 20: Hologic – the opportunity ahead
Hologic – the opportunity ahead Verification and validation Clinical study Manufacturing Second test development and IP 20
Slide 21: Looking ahead
®Lumos DIAGNOSTICS
Slide 22: Promising Outlook
Promising Outlook “ Whilst our financial performance in 1H FY24 was below what we Revenue will recover in 2H FY24 - Hologic IP payment, services income and product sales had planned, we achieved significant and transformative Hologic product development commenced – milestone payments expected milest
Slide 23: Questions
Questions
Slide 24: lumosdiagnostics.com
LUMOS DIAGNOSTICS lumosdiagnostics.com
Slide 25: Appendices
®Lumos DIAGNOSTICS
Slide 26: Company snapshot
Company snapshot Issued capital Share Price & Volume Shares 481.3m Options 85.0m Market capitalization (AUD) Share price A$0.076 Market value A$36.6m Cash (pro-forma – Jan 24) A$9.7m Enterprise value A$26.9m Substantial shareholders Board and management Planet Innovation 14.1% Sam Lanyon Non-Exec Ch
Slide 27: Highly experienced leadership team
Highly experienced leadership team Doug Ward Barrie Lambert Sasha Dopheide, PhD Paul Kase CEO & Managing Director Chief Financial Officer Chief Technology Officer SVP of Commercial Operations Doug Ward has more than 30 years of biotech Barrie Lambert has more than 20 years of Sacha Dopheide, PhD has
Slide 28: Lumos has a compelling and highly competitive offering
Lumos has a compelling and highly competitive offering 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers 3. Clinical validatio
Slide 29: Lumos' POC diagnostic test development engine
Lumos’ POC diagnostic test development engine We are one of the few companies in the POC space that provides these integrated services to partners Product Design Develop Manufacture concepts (generated by Lumos or partners/customers) REVENUE Contract fees Revenue & margin Sales & license payments ST
Slide 30: Strategic partnerships are a key pillar of Lumos' growth plan
Strategic partnerships are a key pillar of Lumos’ growth plan Lumos provides a compelling service offering for leading diagnostics companies • Fully-integrated offering—from concept-to-clinic-to-commercial production • Proprietary reader platform—integrate POC testing with electronic medical records
Slide 31: How we add value to partners
How we add value to partners We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market Customer launch and support Manufacture Clinical studies Verification and validation of Conduct feasibility, requirements planning and de-
Slide 32: lumosdiagnostics.com
LUMOS DIAGNOSTICS lumosdiagnostics.com
Lumos Diagnostics Holdings — H1 FY2024 Earnings Presentation on 6ix